Biomaterial Database

Results of Sotalol (Darob) therapy in ventricular arrhythmias. 1999

D Toporan, and M Stancu, and D Glodan

Clinic of Cardiology St. Ioan Emergency Hospital 13, Vitan-Bârzeşti Street, Bucharest, Romania.

The aim of this prospective study was to evaluate the benefit of Sotalol (Darob) use in the therapy of potential malignant ventricular arrhythmias and in the prophylaxis of potential malignant and malignant arrhythmias; the influence on mortality has also been considered. Eighty four patients (pts) diagnosed with ventricular extrasystoles (68 pts., namely 80.95%), ventricular tachycardia (9 pts., namely 10.71%) and ventricular fibrillation (7 pts., namely 8.34%) were included in this study. They have been monitored clinically, electrocardiographically and echocardiographically at 1,3,6 and 12 months (1 year). The drug was given orally in doses 80-320 mg/day in patients with ventricular extrasystoles and in mean doses of 160 mg/day, for 1 year, to prevent recurrencies of ventricular arrhythmias. CONCLUSIONS 1. In malignant and potential malignant ventricular arrhythmias Darob has been efficient on long term (1 year) in 77.67% cases, while in curative treatment of non-malignant ventricular arrhythmias Darob has been efficient in 68.31% cases. 2. Only minor proarrhythmogenic effects have been noticed for the doses of Darob used in this study. 3. long-term administration of Darob seems to reduce the incidence of cardiovascular deaths (35.30% cardiac deaths and 64.70% non-cardiac deaths have been recorded; p < 0.05). 4. Darob constitutes a drug of choice in postinfarction ventricular arrhythmias therapy, due to the beta-blocking effect, favourable during the ischemic episodes which may trigger arrhythmias.

UI	MeSH Term	Description	Entries
D008297	Male		Males
D008875	Middle Aged	An adult aged 45 - 64 years.	Middle Age
D005260	Female		Females
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000889	Anti-Arrhythmia Agents	Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibers. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.	Anti-Arrhythmia Agent,Anti-Arrhythmia Drug,Anti-Arrhythmic,Antiarrhythmia Agent,Antiarrhythmia Drug,Antiarrhythmic Drug,Antifibrillatory Agent,Antifibrillatory Agents,Cardiac Depressant,Cardiac Depressants,Myocardial Depressant,Myocardial Depressants,Anti-Arrhythmia Drugs,Anti-Arrhythmics,Antiarrhythmia Agents,Antiarrhythmia Drugs,Antiarrhythmic Drugs,Agent, Anti-Arrhythmia,Agent, Antiarrhythmia,Agent, Antifibrillatory,Agents, Anti-Arrhythmia,Agents, Antiarrhythmia,Agents, Antifibrillatory,Anti Arrhythmia Agent,Anti Arrhythmia Agents,Anti Arrhythmia Drug,Anti Arrhythmia Drugs,Anti Arrhythmic,Anti Arrhythmics,Depressant, Cardiac,Depressant, Myocardial,Depressants, Cardiac,Depressants, Myocardial,Drug, Anti-Arrhythmia,Drug, Antiarrhythmia,Drug, Antiarrhythmic,Drugs, Anti-Arrhythmia,Drugs, Antiarrhythmia,Drugs, Antiarrhythmic
D001145	Arrhythmias, Cardiac	Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction.	Arrhythmia,Arrythmia,Cardiac Arrhythmia,Cardiac Arrhythmias,Cardiac Dysrhythmia,Arrhythmia, Cardiac,Dysrhythmia, Cardiac
D013015	Sotalol	An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.	Darob,MJ-1999,Sotalol Hydrochloride,Sotalol Monohydrochloride,MJ 1999,MJ1999
D014693	Ventricular Fibrillation	A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.	Fibrillation, Ventricular,Fibrillations, Ventricular,Ventricular Fibrillations
D015996	Survival Rate	The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.	Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D017180	Tachycardia, Ventricular	An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).	Idiopathic Ventricular Tachycardia,Nonsustained Ventricular Tachycardia,Paroxysmal Supraventricular Tachycardia,Ventricular Tachyarrhythmias,Ventricular Tachycardia,Idiopathic Ventricular Tachycardias,Nonsustained Ventricular Tachycardias,Paroxysmal Supraventricular Tachycardias,Supraventricular Tachycardia, Paroxysmal,Tachyarrhythmia, Ventricular,Tachycardia, Idiopathic Ventricular,Tachycardia, Nonsustained Ventricular,Tachycardia, Paroxysmal Supraventricular,Ventricular Tachyarrhythmia,Ventricular Tachycardia, Idiopathic,Ventricular Tachycardia, Nonsustained,Ventricular Tachycardias